AstraZeneca, Immunai
AstraZeneca in AI Collaboration With Immunai to Inform Cancer Drug Trials
(Reuters) - AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of the immune system to make certain cancer drug trials more efficient, the latter said on Thursday.
AstraZeneca's experimental drug disappoints in breast cancer survival trial
AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly improve overall survival for patients with a type of breast cancer in a late-stage trial.
Immunai, AstraZeneca collaborate to optimize cancer clinical trials
Under the terms of the agreement, AstraZeneca will leverage Immunai’s platform and machine learning capabilities to inform certain oncology clinical trials.
Israeli AI startup forges $18m partnership with AstraZeneca for cancer drug trials
As part of the collaboration, the drugmaker will use Immunai's AI model of the immune system and machine learning for clinical decision-making in drug discovery and development The post Israeli AI startup forges $18m partnership with AstraZeneca for cancer drug trials appeared first on The Times of Israel.
AstraZeneca's experimental cancer drug shows no significant improvement in overall survival
AstraZeneca said on Monday its experimental precision drug developed with Daiichi Sankyo did not significantly improve overall survival for patients with a type of breast cancer in a late-stage trial.
GlobalData on MSN15h
AstraZeneca’s Tagrisso gains FDA approval for stage III NSCLC
Tagrisso, which targets exon 19 deletions or exon 21 (L858R) mutations, received the approval following a priority review.
MM&M12h
AstraZeneca’s ‘What science can do’ campaign highlights company’s scientific achievements
In several short films directed by Reed Morano, the “What science can do” campaign features stories from a cancer patient and an asthma patient.
AstraZeneca rises Thursday, outperforms market
AstraZeneca PLC AZN shares rallied 1.33% to £117.20 Thursday, on what proved to be an all-around great trading session for ...
AstraZeneca's Top-Selling Cancer Drug Tagrisso Receives FDA Green Light For Another Lung Cancer Indication
The FDA has approved AstraZeneca's Tagrisso for treating unresectable, Stage III EGFR-mutated non-small cell lung cancer, ...
FierceBiotech4d
AstraZeneca, Daiichi's Trodelvy rival fails to improve overall survival in breast cancer trial
AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...
FiercePharma1d
AstraZeneca’s Tagrisso follows up ASCO standing ovation with lung cancer FDA nod
In June, at the American Society of Clinical Oncology (ASCO) conference in Chicago, when AstraZeneca discussed results from a ...
AstraZeneca: Buy This Big Pharma Stock At A Discount Now
AstraZeneca topped the analyst consensus for net revenue and matched the analyst consensus for core EPS in Q2. See why I ...
AstraZeneca: FDA Approves Tagrisso To Treat Unresectable Stage III Lung Cancer
British drug major AstraZeneca PLC (AZN, AZN.L) announced Thursday that its Tagrisso (osimertinib) has been approved in the US for ...
STAT12d
News from ESMO: An AstraZeneca win in bladder cancer, and more
AstraZeneca’s Phase 3 study in bladder cancer, showed that giving Imfinzi — before and after surgery — cut the risk of death.
Zacks.com on MSN1d
AstraZeneca Stock Up Almost 14% in 6 Months: Time to Buy?
AstraZeneca AZN stock has risen 13.6% in the past six months, outperforming an increase of 7.1% for the industry. AstraZeneca ...